AB Science to hold its Annual General Meeting of Shareholders on June 30, 2023
30/05/2023 – AB Science will hold its Annual General Meeting on Friday 30 June 2023 at 3.30pm
AB Science summarizes key messages from its participation to a panel discussion at the 2023 ALS Drug Development Summit
17/05/2023 – AB Science today summarizes the key messages delivered to an audience of key opinion leaders and decision-makers in the field of ALS research and healthcare policy, during an Panel Discussion at the ALS Drug Development Summit in Boston, USA (May 16-18, 2023)
AB Science announces that Health Canada has resumed its review of the New Drug Submission for masitinib in amyotrophic lateral sclerosis, following issuance of a screening acceptance letter
09/05/2023 – AB Science today announces that Health Canada has issued a screening acceptance letter for the application of masitinib in the treatment of amyotrophic lateral sclerosis (ALS)
Annual financial results as of 31 December, 2022
28/04/2023 – AB Science reports its revenues for the year 2022 and provides an update on its activities
Summary of the presentation on masitinib in ALS delivered at 2023 AAN Annual Meeting
27/04/2023 – AB Science today summarizes the presentation that was made on masitinib in amyotrophic lateral sclerosis at the American Academy of Neurology (AAN) 2023 Annual Meeting in Boston, USA
Presentation on masitinib in ALS delivered at 2023 AAN Annual Meeting
27/04/2023 – Presentation on masitinib in amyotrophic lateral sclerosis delivered at the American Academy of Neurology 2023 Annual Meeting
Success of the capital increase by private placement for an amount of 15 million euros
24/04/2023 – AB Science announces today the success of its capital increase via a private placement for a final amount of 15.0 million euros
Implementation of a new strategy and launch of a capital increase
21/04/2023 – AB Science announces today the implementation of a new strategy and the launch, in support of this new strategy, of a capital increase
AB Science announces masitinib patent granted in Japan for the treatment of amyotrophic lateral sclerosis, strengthening the Company’s intellectual property position until 2037
18/04/2023 – AB Science today announced that the patent office of Japan has issued a Notice of Allowance (NOA) for a patent relating to methods of treating amyotrophic lateral sclerosis (ALS) with its lead compound masitinib
Results of masitinib in ALS selected for a scientific platform presentation at the AAN 2023, including long-term survival analysis and a new analysis of patient population with no complete loss of function at baseline
12/04/2023 – AB Science today announced that Professor Albert Ludolph, MD, PhD (Chairman of the Department of Neurology at the University Hospital and Medical Faculty of Ulm), will deliver a presentation on masitinib in amyotrophic lateral sclerosis (ALS) to an audience of key opinion leaders in the field of ALS healthcare, at the up-coming American Academy…